Risk or Benefit in Screening for Cardiovascular Disease (ROBINSCA): The Rationale and Study Design of a Population-Based Randomized-Controlled Screening Trial for Cardiovascular Disease

Carlijn M Van Der Aalst^1*, Marleen Vonder², Jan-Willen Gratama³, Henk J Adriaansen⁴, Dirk Kuijpers^2,5, Sabine JAM Denissen¹, Pim Van Der Harst^2,6, Richard L Braam⁷, Paul RM Van Dijkman⁸, Rykel Van Bruggen⁹, Frank W Beltman¹⁰, Matthijs Oudkerk² and Harry J De Koning¹

¹Department of Public Health, Erasmus MC-University Medical Centre Rotterdam, Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

²Center for Medical Imaging North-East Netherlands (CMI-NEN), University of Groningen, University Medical Center Groningen, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

³Department of Radiology, Gelre Hospital, Apeldoorn, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

⁴Clinical chemistry and hematology laboratory, Gelre Hospital, Apeldoorn, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

⁵Department of Radiology, Haaglanden Medical Centre Bronovo, The Hague, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

⁶Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

⁷Department of Cardiology, Gelre Hospital, Apeldoorn, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

⁸Department of Cardiology, Haaglanden Medical Centre Bronovo, The Hague, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

⁹General Practice, Apeldoorn, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

¹⁰General Practice, Groningen, The Netherlands, E-mail: c.vanderaalst@erasmusmc.nl

^*Corresponding Author: Carlijn M Van Der Aalst, Department of Public Health, Erasmus MC P.O. Box 2040, 3000 CA Rotterdam, The Netherlands, Tel: +31107043446, Fax: +311070384 75 Email: